Loading...

Michael Choi

TitleAssistant Clinical Professor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #0820
La Jolla CA 92093
Phone858-534-1765
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 01; 22(6):951-959.e3. PMID: 29859176.
      View in: PubMed
    2. Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biol Ther. 2018 Mar 22; 1-17. PMID: 29565699.
      View in: PubMed
    3. Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R. BRAF mutation as a novel driver of eosinophilic cystitis. Cancer Biol Ther. 2017 Sep 02; 18(9):655-659. PMID: 28829677.
      View in: PubMed
    4. Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017 May 19; 10(1):112. PMID: 28526063.
      View in: PubMed
    5. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. PMID: 28681041.
      View in: PubMed
    6. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240. PMID: 28089635.
      View in: PubMed
    7. Choi MY, Kipps TJ. How Do Targeted Therapies Change the Management of Indolent Lymphomas? Oncology (Williston Park). 2016 09 15; 30(9):859-60. PMID: 27633418.
      View in: PubMed
    8. Choi MY, Kashyap MK, Kumar D. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor. Best Pract Res Clin Haematol. 2016 Mar; 29(1):40-53. PMID: 27742071.
      View in: PubMed
    9. Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016 08; 15(8):1781-91. PMID: 27413114.
      View in: PubMed
    10. Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps TJ, Cardarelli PM, Castro JE. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19; 7(3):2809-22. PMID: 26646452; PMCID: PMC4823073.
      View in: PubMed, PubMed Central
    11. Choi MY, Widhopf GF, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. PMID: 26297272; PMCID: PMC4548279.
      View in: PubMed, PubMed Central
    12. Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015 Jul; 14(7):1650-60. PMID: 25934707; PMCID: PMC4557793.
      View in: PubMed, PubMed Central
    13. Stout EP, Choi MY, Castro JE, Molinski TF. Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies. J Med Chem. 2014 Jun 26; 57(12):5085-93. PMID: 24673739; PMCID: PMC4079331.
      View in: PubMed, PubMed Central
    14. Choi MY, Kipps TJ. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012 Sep-Oct; 18(5):404-10. PMID: 23006944; PMCID: PMC3461329.
      View in: PubMed, PubMed Central
    15. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 09; 108(32):13253-7. PMID: 21788521; PMCID: PMC3156152.
      View in: PubMed, PubMed Central
    Michael's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (110) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (16) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑